---
schema_version: "secwatch.filing_event.v1"
accession: "0001625297-25-000035"
form_type: "8-K"
ticker: "INDV"
cik: "0001625297"
company_name: "Indivior Pharmaceuticals, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:57:03.047898+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Indivior to cancel London Stock Exchange secondary listing, maintain Nasdaq primary listing

## Summary
- London delisting effective July 25, 2025; last trading on LSE July 24, 2025.
- Over 80% of net revenue from US; 75% of trading volume on Nasdaq; over 70% of shareholders by value US-based.
- Nasdaq listing under INDV unaffected; direct holders and DTC broker/custodian holders unaffected.
- Holders of UK Depositary Interests and Corporate Sponsored Nominee facility advised to convert holdings for Nasdaq trading.
- UK Takeover Code remains applicable for 2 years after delisting; mandatory offer rules unchanged.

## SEC filing metadata
- accession: 0001625297-25-000035
- form_type: 8-K
- ticker: INDV
- cik: 0001625297
- company_name: Indivior Pharmaceuticals, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625297/000162529725000035/0001625297-25-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625297/000162529725000035/a8-k05302025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001625297-25-000035
- JSON: https://secwatch.observer/filing/0001625297-25-000035.json
- Plain text: https://secwatch.observer/filing/0001625297-25-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.